Literature DB >> 26938274

Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis.

Silvia Gobbi1, Qingzhong Hu2, Christina Zimmer2, Matthias Engel2, Federica Belluti1, Angela Rampa1, Rolf W Hartmann2, Alessandra Bisi1.   

Abstract

The inhibition of corticosteroid biosynthesis could be considered as an emerging strategy to reduce their abnormally high levels, and in this framework CYP11B1 and CYP11B2 represent the most promising targets. In continuing our studies on flavonoid-like scaffolds as privileged structures in medicinal chemistry, in this paper we describe a small library of pyridyl- and imidazolylmethylchromones as potential inhibitors of these enzymes. Testing results proved that position 3 of the chromone scaffold is the most favorable for the introduction of the heme-coordinating heterocycles and, among them, the 4-imidazolyl moiety is the most convenient for the interaction with the heme iron of the selected cytochromes. A low nanomolar inhibitor of CYP11B1 (5c) was obtained, endowed with reasonable selectivity toward CYP11B2 and able to better discriminate with respect to CYP17 and CYP19.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26938274     DOI: 10.1021/acs.jmedchem.5b01609

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Human cytochrome P450 11B2 produces aldosterone by a processive mechanism due to the lactol form of the intermediate 18-hydroxycorticosterone.

Authors:  Michael J Reddish; F Peter Guengerich
Journal:  J Biol Chem       Date:  2019-07-11       Impact factor: 5.157

2.  Pharmacophore Modeling and in Silico/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors.

Authors:  Muhammad Akram; Watcharee Waratchareeyakul; Joerg Haupenthal; Rolf W Hartmann; Daniela Schuster
Journal:  Front Chem       Date:  2017-12-19       Impact factor: 5.221

3.  Beyond the Antagonism: Self-Labeled Xanthone Inhibitors as Modeled "Two-in-One" Drugs in Cancer Therapy.

Authors:  Fu-Chao Yu; Xin-Rong Lin; Zhi-Cheng Liu; Ji-Hong Zhang; Fei-Fei Liu; Wei Wu; Yu-Lu Ma; Wen-Wen Qu; Sheng-Jiao Yan; Jun Lin
Journal:  ACS Omega       Date:  2017-03-13

4.  First total synthesis of chromanone A, preparation of related compounds and evaluation of their antifungal activity against Candida albicans, a biofilm forming agent.

Authors:  Iván Cortés; Estefanía Cordisco; Teodoro S Kaufman; Maximiliano A Sortino; Laura A Svetaz; Andrea B J Bracca
Journal:  RSC Adv       Date:  2021-06-01       Impact factor: 4.036

Review 5.  From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.

Authors:  Jazmín Alarcón-Espósito; Michael Mallea; Julio Rodríguez-Lavado
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.